Nanoviricides (NNVC) Cash from Financing Activities (2010 - 2026)
Nanoviricides (NNVC) posted Cash from Financing Activities of -$6742.0 for Q1 2026, down 100.11% sequentially from $6.1 million in Q4 2025, and down 101.17% YoY from $575503.0 in Q1 2025.
Nanoviricides (NNVC) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Nanoviricides has reported Cash from Financing Activities for 13 years, with the latest figure at -$6742.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 101.17% year-over-year to -$6742.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (up 4.59% YoY) and the FY2025 annual result came in at $5.3 million, up 69.76% from the prior year.
- Cash from Financing Activities retreated to -$6742.0 in Q1 2026 per NNVC's latest filing, from $6.1 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $6.1 million in Q4 2025 and troughed at -$70951.0 in Q3 2022.
- A 4-year average of $1.3 million and a median of $651791.5 in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities soared 166.11% in 2025, then sank 101.17% in 2026.
- Over 4 years, Cash from Financing Activities stood at -$23837.0 in 2022, then soared by 9676.32% to $2.3 million in 2024, then soared by 166.11% to $6.1 million in 2025, then sank by 100.11% to -$6742.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$6742.0, $6.1 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | -6,742.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,742.00 |
| Mar 31, 2026 | -6,742.00 |
| Dec 31, 2025 | 6.07 Mn |
| Dec 31, 2025 | 6.07 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 728,080.00 |
| Jun 30, 2025 | 728,080.00 |
| Mar 31, 2025 | 575,503.00 |
| Mar 31, 2025 | 575,503.00 |
| Dec 31, 2024 | 2.28 Mn |
| Dec 31, 2024 | 2.28 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Dec 31, 2022 | -23,837.00 |
| Dec 31, 2022 | -23,837.00 |
| Sep 30, 2022 | -70,951.00 |
| Sep 30, 2022 | -70,951.00 |